Real-world challenge for clinicians treating advanced gastroesophageal adenocarcinoma (Review)

MARK A. BAXTER1,2, RUSSELL D. PETTY1,2, DANIEL SWINSON3, PETER S. HALL4 and SHANE O’HANLON5

1Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee DD2 1SY, Scotland; 2Tayside Cancer Centre, Ninewells Hospital and Medical School, NHS Tayside, Dundee DD1 9SY; 3Department of Oncology, St. James’s Hospital, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF; 4Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh EH4 2XR, Scotland, UK; 5Department of Geriatric Medicine, St. Vincent’s University Hospital, Dublin 4, D04 N2E0, Republic of Ireland

Received November 12, 2020; Accepted March 4, 2021

DOI: 10.3892/ijo.2021.5202

Abstract. Gastroesophageal adenocarcinoma (GOA) is a disease of older people. Incidence is rising in the developed world and the majority of patients present with advanced disease. Based on clinical trial data, systemic chemotherapy in the advanced setting is associated with improvements in quality of life and survival. However, there is a recognised mismatch between trial populations and the patients encountered in clinical practice in terms of age, comorbidity and fitness. Appropriate patient selection is essential to safely deliver effective treatment. In this narrative review, we discuss the challenges faced by clinicians when assessing real-world patients with advanced GOA for systemic therapy. We also highlight the importance of frailty screening and the current available evidence we can use to guide our management.

Contents

1. Introduction
2. Patient experience and the role of the multi-disciplinary team
3. Treatment challenges in advanced gastroesophageal adenocarcinoma
4. Trial evidence for practice
5. Future direction
6. Conclusion

1. Introduction

The two major histological subtypes of gastroesophageal cancer are adenocarcinoma and squamous cell carcinoma. Gastroesophageal adenocarcinoma (GOA) is the most common histological subtype in developed countries and the incidence of GOA has markedly increased in the Western world in the last 40 years due to a rise in gastroesophageal reflux disease (GORD) and obesity (1).

GOA is a disease affecting older-aged individuals (2,3). In the United Kingdom (UK), the median age at diagnosis is 74 years and there are approximately 15,000 cases diagnosed annually (2). As the population ages, this figure is projected to continue to rise, particularly in patients aged ≥80 years (4).

Patients with GOA often have a high symptom burden and frequently have a reduced performance status and features of frailty (3,5,6). It is therefore becoming crucial to understand how to best tailor treatments for the older-aged, frail patients with GOA in clinical practice.

Between 60 and 80% of patients with GOA present with advanced stage disease not amenable to curative treatment approaches with surgery or definitive chemoradiotherapy, or present when curative treatment is not possible due to medical co-morbidities or frailty (7,8). The focus of treatment in these patients is disease control and the palliation of symptoms. There is ample evidence to suggest that systemic anticancer therapy in the form of chemotherapy can achieve this. Systemic treatment has also been shown to improve the health-related quality of life (9). However, at diagnosis,
The median overall survival (OS) is approximately 3 months with the best supportive care (9,11) and reported as 9-11 months with chemotherapy, extending to 16 months with the addition of trastuzumab to the subgroup (approximately 20%) of patients whose tumours are human epidermal growth factor receptor 2 (HER2)-positive (12,13). Emerging data suggest a role for immune checkpoint inhibitors (ICIs) in selected patients, which may provide more durable responses and result in a prolonged treatment duration, particularly in patients with an increased programmed death-ligand 1 (PD-L1) expression or mismatch repair deficiency (14,15).

In those patients with advanced GOA who are deemed fit for systemic therapy, there is often a mismatch between their clinical phenotype and that observed in trial populations on which treatment guidelines are based. Clinicians are therefore required to apply information extrapolated from clinical trials in which patients are younger, fitter and have fewer comorbidities (16). This creates uncertainty around regime and dose due to concerns regarding the risk of toxicity with age-related changes to pharmacokinetics and pharmacodynamics. Ultimately this can result in the undertreatment of a patient and/or excess morbidity and mortality (17).

Despite this, trial data suggest that older-aged patients with advanced GOA can tolerate and benefit from systemic chemotherapy (18). As such, chronological age should not by itself preclude the use of anticancer therapy. Rather, a global picture of the patient’s health should be considered, including functional status, comorbidities and social support. Frailty screening and comprehensive geriatric assessment (CGA) along with allied healthcare professional involvement should be part of this process (19).

The present narrative review discusses the challenges associated with the assessment of older-aged patients with advanced GOA and frailty that is commonly encountered in real-world clinical practice, the importance of frailty assessment and the current evidence which underpins our treatment decisions.

2. Patient experience and the role of the multi-disciplinary team

At diagnosis, the patient population with advanced GOA is characterised by an older age, a high symptom burden and a poor prognosis. For patients not fit to receive systemic treatment, the median OS is poor, estimated at 3 months (11). Contributing factors include the stage of disease and performance status; however, age does not appear to have an impact (18).

For patients who receive systemic therapy, there is a median OS benefit of approximately 6.7 months over supportive measures alone (20) and evidence to support improvement in symptoms (9). However, >50% of patients require at least one treatment-related hospital admission, and 96% report fatigue (21). In all patients, there is a fine balance between the palliation of symptoms, improving survival and the risk of toxicity negatively impacting the quality of life.

Due to the nature of the disease, patients of all ages have often had a period of nutritional deficit. This, coupled with the high catabolic state of advanced disease, can result in malnutrition, immunodeficiency, an impaired quality of life and worse clinical outcomes (22). The impact is more evident in older-aged patients where age-related nutritional consequences, such as sarcopenia and osteoporosis are more common (23) and where other comorbidities are prevalent (24). In adults aged ≥60, the prevalence of malnutrition varies according to the setting, estimated at 3.1% in the community to 28.7% in long-term care (25). This has important implications when assessing a patient's suitability for treatment. The treatment of advanced GOA therefore requires a multidisciplinary approach (Table I) with specific focus on input from palliative care, physicians with geriatric expertise (if available), general practice (GP), dietetics, occupational therapy and physiotherapy (26).

The medical team. Patients experience a high symptom burden in their final year of life (5). Symptoms related to tiredness, well-being and appetite become more severe earlier in the disease course, whereas symptoms related to drowsiness, pain and shortness of breath become more severe closer to death (5). The impact of symptom burden on both patients and the health service, was demonstrated by a study in Scotland, which found that 75% of patients with upper gastrointestinal cancer use GP out-of-hours services in the last year of life with a further 7.8% using hospital emergency departments (EDs) and 22.6% using both GPs and EDs (27). In addition, patients with advanced GOA who survive <7 months following diagnosis, have an association with several indicators of low-quality end-of-life care (28).

Outpatient palliative care initiation has been shown to be associated with a decrease in symptoms and early palliative care involvement improves the quality of life at the end stages of life and reduces hospital visits (29). This highlights the importance of early cross-specialty collaboration.

Allied healthcare professionals. Cancer and its treatment can have an impact on a number of domains of a patient’s health. It is therefore essential to assess for and address any functional, social or cognitive deficits early in the patient cancer journey. This can be done using frailty screening tools and a CGA, which will be discussed in detail below.

An example is the impact of cancer on the metabolic state of a patient, exacerbated in GOA by dysphagia. Systemic therapy can compound this further by causing symptoms, such as nausea, vomiting, mucositis and diarrhoea. The consequence is malnutrition, which in turn can influence the effectiveness of chemotherapy (30). A proportion of patients will require stent insertion to maintain oral intake, but all patients should receive regular nutritional assessments and dietetics input, as this has been shown to improve the quality of life and outcomes (31). In those who undergo stent insertion, close nutritional observation is required due to post stent pain.

Physical activity following a diagnosis of advanced cancer has the potential to prevent or reverse functional decline, control cancer-related symptoms and help maintain independence, thus improving outcomes (32). Older-aged patients with cancer are at an increased risk of falls compared to the general population (33) and prior falls are associated with a risk of
Frailty. Frailty is defined as a state of increased vulnerability toward stressors due to a multisystem reduction in reserve capacity (45). It is linked to both chronological age and the presence of comorbidities, but is considered a distinct concept. Frailty is common in cancer, both due to the association of cancer with certain comorbidities and the increasing age, but also as the cancer itself places a physiological strain on the health of an individual. There are different models of the concept of frailty and no single diagnostic test. This means it is not possible to state an exact prevalence of frailty in older-aged patients with cancer.

A systematic review in 2015 evaluated data from 2,916 participants in 20 studies of frailty in older cancer patients (6). Studies were included if they used one or more of the established frailty models (phenotype model, cumulative deficit model or CGA). They found that the median reported prevalence of frailty and pre-frailty was 42% (6-86%) and 43% (13-79%), respectively. Only a median of 32% (11-78%) were classified as fit. Importantly, few patients included in the review had GOA and there is therefore a paucity of data relating specifically to prevalence of frailty in advanced GOA. Patients deemed frail or pre-frail were at increased risk of chemotherapy toxicity and intolerance as well as all-cause mortality.

Consequently, screening for frailty prior to commencing therapy is a useful step to identify a population that is at higher risk for toxicity. This screening should prompt more detailed investigation of specific patient needs. This is usually done by CGA, which not only identifies issues but also involves the intervention and follow-up.
Traditionally, oncologists have used the Eastern Cooperative Oncology Group (ECOG) performance status (PS) or the Karnofsky performance scale as measures of fitness and frailty. Although very quick to do, they were validated in younger populations and do not take into account contributing domains of frailty such as medications, comorbidity and cognition (34) or interuser variability (46). They have also been shown to be inferior to other frailty screening tools and therefore should not be used alone (47).

Due to time limitations in clinical practice, a number of screening tools for frailty have been developed and validated with a focus on identifying patients who require a more in-depth assessment in the form of a CGA.

The Clinical Frailty Scale (48) also known as the Rockwood Score, is the most commonly used tool in the UK due to its ease of use and availability. It is based on clinical assessment using knowledge of cognition, social support, comorbidity and function. The patient is assigned a score between one and nine based on activity, function and disability. Other screening tools used in a cancer setting are the Geriatric 8 (G8) (49), Vulnerable Elders Survey-13 (50), the abbreviated CGA (51) and the Groningen Frailty Indicator (GFI) (52).

A screening tool may prompt the implementation of a CGA. This is used to identify causes of frailty, and target interventions appropriately (53). It is a detailed process with interdisciplinary input, which assesses multiple domains to create a problem list and subsequent plan of management. Although it is a strong predictor of adverse events with chemotherapy (19), its use in clinical practice is limited by time-constraints and the need for a physician with geriatric expertise. The implementation of CGA in gastrointestinal cancer has been shown to improve tolerance to chemotherapy, reduce dose modifications and lower rates of grade 3-5 toxicity (54,55). A CGA should therefore be a standard of care for patients with advanced GOA deemed to have features of frailty.

**Drug-related issues**

**Age-related changes.** Physiology changes with age. This can have an impact on drug pharmacokinetics and pharmacodynamics (56). The age-related decline in renal function, as well as liver volume and blood flow impact the excretion and metabolism of drugs. In gastroesophageal cancer, this can be compounded by reduced gastric motility and absorption. A further complication is the age-associated reduction in lean body weight and muscle mass, which can impact the volume of distribution of lipid-soluble drugs. Taken together, these factors render the older-aged population more prone to drug-related side-effects, particularly when symptom control becomes a priority at the end of life.

**Polypharmacy.** Patients with advanced GOA, prior to their diagnosis, will often have multiple co-morbidities with associated prescribed medications. A UK study in patients with advanced cancer found the median number of medications was 7 (57). In that study, the median age and PS were 73 years and 2 respectively, similar to the advanced GOA population which is encountered.

In the context of SACT, a number of regimes involve the prescription of drugs that are inherently toxic and have narrow therapeutic windows. In addition, regimes often have supportive medications adding to the medication burden. This can potentially lead to poor adherence or inappropriate medication use (58). In advanced GOA, a good example of a common drug interaction is the reduction in the efficacy of capecitabine if co-prescribed with a proton pump inhibitor (59). This has been shown to impact both progression-free survival (PFS) and OS. It is therefore vital to rationalise medications whenever possible.

**Nutritional support.** Malnutrition is an important prognostic factor in all cancer patients. Approximately 10-20% of cancer-related deaths can be predominantly attributed to malnutrition as a consequence of the cancer itself (60,61). A poor nutritional state is associated with poorer outcomes, such as lower response rates and survival, increased toxicity and a reduced quality of life (62-64). An age >70 years is associated with a 2-fold increased risk of cancer mortality and severe malnutrition a 2.5-fold increased risk (61).

Advanced GOA can significantly affect nutrition with dysphagia and anorexia being common symptoms. In a study on 1,000 cancer outpatients, the median percentage weight loss for oesophageal and gastric cancers was 15.9 and 11.0%, respectively (65). In these patients, weight loss was associated with anorexia and was greater in those with more advanced disease and with compromised performance status.

The recognition and management of nutritional issues is of particular importance in older-aged patients as they are predisposed to age-related reductions in lean muscle mass (sarcopenia) (66), as well as reduced gastrointestinal absorption (67). There is an additional challenge of delineating normal age-related changes from pathological cancer-related changes. In advanced gastric cancer, there is evidence that malnutrition exists in over half of patients and that it is associated with greater stage, elevated inflammatory markers and significantly lower survival (68). Nutritional assessment and subsequent intervention have been observed to improve survival.

**Chemotherapy risk assessment tools.** Chemotherapy toxicity can have a significant impact on a patient’s quality of life. Toxicity occurring in the first cycle of treatment can predict those patients who will develop severe toxicity (69). Toxicity can result in reduced survival as a consequence of reduced dose intensity. The ability to predict which patients are more likely to develop side effects would facilitate a proactive approach, either dose reduction or the initiation of supportive measures. The goal for clinicians is to maintain efficacy of treatment, while minimising the negative impact on quality of life.

In advanced GOA, in a standard of care epirubicin/oxaliplatin/capecitabine (EOX) arm of the REAL2 trial (13), 42% of patients required a dose reduction and 50% of patients required at least one dose delay due to treatment-related toxicity (13). In the GO2 trial in a frail population, even with a 60% dose, 86% of patients experienced some form of toxicity and 37% experienced grade ≥3 toxicity (70).

At present, there is no validated chemotherapy toxicity tool specifically for advanced GOA. There are two tools in general use that have been validated in a range of solid and haematological malignancies, the Cancer and Aging Research Group (CARG) tool and Chemotherapy Risk Assessment Scale for High-Age patients (CRASH) score. The CARG tool and CRASH score were developed as tools to predict severe
toxicity in older-aged patients (34,71). They use baseline patient and treatment factors to calculate a risk score and are more predictive of toxicity than age or performance status.

Although validated (72), their use is limited in advanced GOA due to a lack of agreement in which factors are important, the wide range of chemotherapy regimes and settings included and the low numbers of GOA patients. These limitations, coupled with the knowledge that the GOA population differ from other tumour types, highlight the need for a toxicity prediction tool specific to advanced GOA.

4. Trial evidence for practice

There have been a limited number of oncology studies focused on an older, frailler population treated with chemotherapy. The majority of the data used in clinical practice comes from retrospective data collection or sub-analysis of larger trials which included older patients within their eligibility criteria (Table II). When applying these data, consideration should also be given to the end points used, the traditional endpoint of OS may be less appropriate in an older population. Other outcomes, such as quality of life, the maintenance of a functional status and cognition may be as relevant or even more relevant than survival (73).

First-line chemotherapy. In advanced GO cancer, a standard of care chemotherapy in younger patients with a good PS (PS 0-1) was established by the REAL2 trial (13). In that trial, the median age of the EOX arm was 62 years and 90% of patients had PS 0 or 1. In patients with features of frailty and reduced PS, a standard of care was established by the recently presented GO2 trial (70).

Prior to the GO2 trial, there was a lack of data in elderly, frail patients. Several phase I/II studies were conducted in the 1990s/early 2000s to investigate the use of chemotherapy in older patients with gastric cancer. Overall response rates (RRs) ranged from 29 to 45%, with median PFS 4.2-5 months (74-77).

The only large, randomised trial in advanced GO cancer was the COMBAT study (78). That study tested the addition of mitomycin C to infusional 5-fluorouracil (5FU), demonstrating no statistically significant advantage in the primary endpoint, failure-free survival (FFS). The median age was 72, 32% were PS 2 and the median OS was 6.3 months.

A pooled analysis in 2006 of three UK clinical trials in advanced GO cancer compared outcomes in patients aged >70 years to younger patients (18). A total of 1,080 patients were included, of whom 257 (23.8%) were >70 years of age. No significant differences in RR, survival or toxicity were observed. A further study by the North Central Cancer Treatment Group (NCCTG) in which 154 patients were aged >65 years, found that although OS and RR were similar, the rates of toxicity were higher than those compared to patients younger, <65 years of age (79).

In 2015, the Phase II TTD 08-02 study assessed the use of a triplet regime in the form of reduced dose docetaxel with oxaliplatin and capecitabine in 42 ‘sub-optimal’ patients. These patients were defined as those with PS 2, weight loss 10-25% and/or aged ≥70 years. Although the median OS was 13.4 months, the rate of grade 3-5 toxicity was 76%, with 3 (7%) patients suffering a sudden death (80). Due to the high toxicity, this regime has not been adopted.

These studies suggested that three drug platinum-based chemotherapy often provided an unequal balance of toxicity over efficacy for older and frailer patients. This opinion was reflected in guidelines for GOA (81), and despite the lack of randomised trial evidence oncologists commonly made empirical dose reduction to chemotherapy in those older and frailer patients for whom there was concern that they would not tolerate standard dose three drug regimens.

To address the question of appropriate dosing in a frailler population a Phase II feasibility study in the UK, 32IGO, was undertaken (16). It concluded that it was feasible to recruit older and/or frail patients with advanced GO cancer to a randomised clinical trial and that OX (oxaliplatin/capecitabine) was the preferred regimen for further study. That study also supported the use of the novel composite endpoint, overall treatment utility (OTU), including both patient-reported and clinical indices. This was initially used in the FOCUS2 trials in colorectal cancer (82) and reflects whether either or both the patient and clinician were pleased with the decision to proceed with chemotherapy (Table III).

The subsequent GO2 trial (70) aimed to establish the optimum dose-intensity (100, 80 or 60%) of two-drug OX palliative chemotherapy in patients who are considered unsuitable for triplet EOX chemotherapy. The goal was to achieve the best balance of cancer control, toxicity, patient convenience, acceptability and quality of life. That study also aimed to establish pre-treatment patient characteristics which predict for better or worse outcomes with chemotherapy at different dose intensities.

A total of 517 patients were recruited, and the population appeared representative of real-world experience, median age 76 years, 31% PS ≥2 and >50% classified as very frail. The 60% dose was found to be non-inferior to 100% dose [median OS, 7.6 vs. 7.5 months; hazard ratio (HR), 1.10] with reduced toxicity (grade 3+ adverse events, 37 vs. 56%) and better OTU (good OTU, 43 vs. 35%). On sub-analysis, no group was found to benefit from the higher dose, and the fittest patients benefited most from dose reduction. Age and PS were not predictive of OTU; however, this may be due to higher numbers of fit elderly patients and unfit younger patients within the trial.

As a result of that trial, the new ‘full dose’ standard of care treatment for patients with advanced GOA and features of frailty is 60% of the dose of oxaliplatin and capecitabine used in the REAL2 trial. Of note, in a sub-study of the GO2 trial, which recruited 45 patients in whom there was doubt over the benefit of giving chemotherapy, there was no significant survival advantage for single drug capecitabine over best supportive care (median OS, 6.1 vs. 3.0 months; HR, 0.64; P=0.34) (11).

Subsequent chemotherapy. When disease progression occurs during or following first-line treatment, only approximately 50% of patients are fit to receive further therapy (83). These patients are often frail as a result of their disease progression (3). In this setting, fewer older-aged patients are offered further treatment compared to younger patients (84). Second line chemotherapy options for advanced GOA include irinotecan, docetaxel and weekly paclitaxel administration.
Table II. Practice changing clinical trials in advanced GOA, which included patients of an older age and with a higher performance status.

| Trial/(Refs.), year | Regime | Population | Median age (range), years | Patient fitness | Relevant data for older adults/frailty/increased PS |
|---------------------|--------|------------|---------------------------|----------------|--------------------------------------------------|
| **First line chemotherapy** | | | | | |
| REAL2 (13), 2008 | EOX vs. ECX vs. n=239 in EOX (87.4% GOA) ECF vs. EOF PS 0/1: 90% PS 2: 10% PS 2, >70 years or weight loss 10-25% | 62 (25-80) | No data published data regarding PS 2 and age. |
| TTD08-02 (80), 2015 | Mini-DOX n=42 'sub-optimal patients' defined as PS 2+, >70 years or weight loss 10-25% | 73.3 (40.2-87.7); 65% >70 years | 5.5 Months (3.8-7.2) 13.4 Months (7.7-19.6) 76.2% Grade 3-5 toxicity; prophylactic G-CSF introduced for last 33 patients. |
| GO2 (70), 2019 | OX Level A (100%) 170 PS: ≥2 31% 4.9 Months 7.5 Months Grade 3+ toxicity 56% | 76 | 4.1 Months 6.7 Months 37% |
| | Level B (80%) 171 PS: ≥2 32% 4.3 Months 7.6 Months 56% | 76 | |
| | Level C (60%) 173 PS: ≥2 31% 4.3 Months 7.6 Months 37% | 77 | |
| **Subsequent line chemotherapy** | | | | | |
| COUGAR-02 (88), 2014 | Docetaxel vs. BSC GOA (n=84 and 84) | 65 (28-84) vs. 66 (36-84) Age >70: 23 (27%) vs. 16 (19%) Docetaxel: ITT: 12.2 weeks. ITT: 5.2 vs. 21% Grade 4 toxicity | 21% Grade 4 toxicity |
| German AIO (87), 2011 | Irinotecan vs. BSC Gastric (n=21 and 19) | 58 (43-73) and 55 (35-72) PS 0/1: 17 (81%) and 14 (74%) PS 2: 4 (19%) and 5 (26%) | 4.9 vs. 2.4 months; HR PS 0/1 vs. PS 2=0.53, P=0.1 26% Grade 3 diarrhoea 16% grade 3+ neutropenic fever |
| WGOJ4007 (101), 2013 | Paclitaxel vs. irinotecan Gastric (n=108 and n=111), Asian population | 64.5 (37-75) and 65 (38-75) PS 0/1: 104 (96.3%) and 107 (96.4%) PS 2: 4 (3.7%) and 4 (3.6%) | 3.6 vs. 2.3 months; HR, 1.14; P=0.33 No breakdown by age or performance status |
| | | | 9.5 vs. 8.4 months (HR, 1.13, P=0.38); HR ≥65, 0.97 HR PS 2: 7.27 (0.79-66.6) favouring paclitaxel |
| Trial/(Refs.), year | Regime | Population | Median age (range), years | Patient fitness | PFS | OS | Toxicity |
|-------------------|--------|------------|--------------------------|----------------|-----|----|----------|
| **Targeted therapy** | | | | | | | |
| TOGA (12), 2010   | CX + herceptin vs. CX alone in 1st line | GO cancer (n=294 and n=290) | 59.4 (1.08) and 58.5 (11.2) 305 patients >60 years | PS 0/1: 264 (90%) and 263 (91%) PS 2: 30 (10%) and 27 (9%) | 6.7 vs. 5.5 months (HR, 0.71, P=0.0002) | PS of 2 > 60 years, therefore no OS advantage For those aged 60+, OS HR 0.66 Grade 3+ toxicity 68% both groups; toxicity similar across ages |
| RAINBOW (92), 2014 | Ramicirumab + paclitaxel vs. paclitaxel alone in 2nd line | GO cancer (n=330 and n=335) | 61 (25-83) and 61 (24-84) >65 years: 126 (38%) and 123 (37%) | PS 1: 213 (65%) and 191 (57%). No PS 2. Weight loss >10%: 53 (16%) and 47 (14%). | 4.4 vs. 2.9 months (HR 0.635, P<0.0001) | Grade 3+ toxicity 83 vs. 65% |
| REGARD (91), 2014  | Ramicirumab vs. BSC | GO cancer (n=238 and n=117) | 60 (52-67) and 60 (51-71) | PS 1: 171 (72%) and 85 (73%). Only 1 patient was PS 2; weight loss >10%: 41 (17%) and 20 (17%) | 2.1 vs. 1.3 months (HR, 0.483; P<0.0001) | Grade 3+ toxicity 57 vs. 58% |
| **Immune checkpoint inhibitors** | | | | | | | |
| KEYNOTE-062 (14), 2020 | Pembrolizumab vs. pembrolizumab + CTx vs. CTx alone | 1st line GO cancer (n=256, 257, 250) | ITT: 62 (20-87) 216 patients >65 | PS 1: 48.8% vs. 53.7% vs. 54% No patients with PS 2 | No survival advantage for age ≥65 with addition of pembrolizumab in any group Grade 3+ toxicity: 16.9% vs. 73.2% vs. 69.3%; immune-mediated adverse events: 21% vs. 24% vs. 8%; no data for age |
There is limited trial evidence for those who are older or of reduced performance status; however, extrapolated data exists that, for those who have PS 2, and to a certain extent 1, the efficacy of further systemic therapy is minimal (85). In the second line COG study which did not stratify according to performance status, the median OS was 6.07, 3.93 and 1.97 months for patients with PS 0, 1 and 2, respectively (86) highlighting the poor survival in those with a reduced PS.

The German AIO trial (87) and the COUGAR-02 trial (88) demonstrate efficacy from cytotoxic agents, such as irinotecan and docetaxel, respectively in the second line setting. However, the benefits of these treatments in the population as a whole were minimal and the toxicity was significant.

The German study of irinotecan included only 9 patients with a performance status of 2. Despite this fact, these patients had a poorer outcome than those with PS0 or 1 (HR, 0.53). The COUGAR-02 trial included 39 patients aged ≥70 and 26 patients with PS 2. Patients with a performance status of 0 had a better OS than those with a performance status of 1 [HR, 2.00; 95% confidence interval (CI), 1.35-2.96] or 2 (HR, 2.16; 95% CI, 1.27-3.66). On the whole, this supports the lack of efficacy of subsequent line therapy in frailer patients with a poor PS.

Beyond second line, the recently published TAGS trial (89) demonstrated a 2.1 month median OS advantage for lonsurf (trifluridine/tipiracil) when compared to supportive care. Lonsurf has now been licenced in the third line setting in the UK. However, only patients with PS 0 or 1 were recruited and the median age of patients recruited was 63. The grade 3+ toxicity rate was 53% and patients aged >65 who received Lonsurf (n=154), although trending for a survival advantage did not meet significance (HR, 0.73; 95% CI, 0.52-1.02).

Targeted agents. In HER2-positive advanced GOA, following the results of the ToGA trial, there is the option to add trastuzumab to a chemotherapy backbone if left ventricular (LV) function permits (12). This is an important consideration in elderly patients, as LV function decreases with age (90). Within the ToGA trial, 57 patients had a PS of 2 and 305 patients were aged ≥60 years of age. There was no survival advantage for those with a PS of 2 (HR, 0.96), but a significant survival advantage for those aged ≥60 years of age. There was no survival advantage for those with a PS of 2 (HR, 0.96), but a significant survival advantage for those aged ≥60 years of age (HR, 0.66). This supports the hypothesis that age alone should not be used as the deciding factor in treatment decisions. Toxicity was similar according to age. Despite the low incidence of cardiac events within the trial, all patients require baseline cardiac imaging prior to starting trastuzumab in addition to ongoing monitoring.

Another licenced targeted agent is the vascular endothelial growth factor receptor (VEGFR)-2 monoclonal antibody, ramucirumab. The REGARD (91) trial demonstrated a survival benefit for ramucirumab over supportive care in the second line setting of 1.4 months. The majority of patients in the trial were performance status 1; only 1 patient was PS 2 and they did not receive the trial drug. However, given that clinicians were prepared to randomise to supportive care and only 35% of patients went on to receive subsequent therapy, PS may not provide an accurate representation of the frailty of the cohort. Therefore, although the survival benefit is minimal, the toxicity profile of ramucirumab is favourable, rendering this a more feasible option for subsequent therapy in frail patients.

Table II. Continued.
3+ toxicity was high at 59% in the combination arm (15). Importantly, despite this apparently fit population, grade 3+

toxicity was 69% with chemotherapy and 73% with the addition of pembrolizumab. The REGARD trial subsequently examined ramucirumab in addition to paclitaxel in the second line setting compared to paclitaxel alone (92). The addition of ramucirumab significantly improved OS (9.6 vs. 7.4 months, P=0.017) with only a minimal increase in toxicity. Again, only PS 0 or 1 patients were included but the PFS and OS was again preserved for PS and age. Of note, rates of neutropenia were higher for those aged >65. Taken together, the REGARD and RAINBOW trials provide an option for subsequent line therapy in those patients in whom there are concerns over toxicity.

**Immune-checkpoint inhibitors.** The advent of immune-checkpoint inhibitors has altered the treatment paradigm for several tumour groups. These agents have a more favourable toxicity profile than traditional chemotherapy in an older population with preserved efficacy (93).

Evidence for their use in advanced GOA is increasing; however, similar to trials with chemotherapy, there is a mismatch between real-world and trial populations. An example is the recent Keynote-061 trial in advanced GO cancer where no patients >70 years of age were included and the only patient with PS 2, did not receive the trial drug (94).

In the first-line setting, the Keynote-062 trial included no patients with PS 2 and >50% had PS 0 (14). Of note, 216 patients were aged ≥65 years and there did not appear to be a survival advantage in this group with the addition of pembrolizumab. Importantly, despite this apparently fit population, grade 3+ toxicity was 69% with chemotherapy and 73% with the addition of pembrolizumab.

Likewise, the CheckMate 649 trial did not include patients with PS 2 and the median age was 63 years. Of the patients included, 59% had PS 1 and the median OS was 12.6 months, compared to 17.6 months in patients with PS 0. Again, grade 3+ toxicity was high at 59% in the combination arm (15).

This highlights the challenge of combination therapy which will likely have important implications in real-world clinical practice.

**Radiotherapy.** The recently published ROCS study (95) investigated the role of palliative radiotherapy in patients who had had a self-expanding oesophageal stent inserted for dysphagia. The median age was 72 years in the radiotherapy group and only 10% of patients had PS 0. No improvement in time to dysphagia deterioration or overall survival was observed with the addition of radiotherapy compared to the usual care group. However, for patients considered to be at high risk of bleeding, concurrent palliative radiotherapy may reduce bleeding risk.

**Early supportive care.** As mentioned above, advanced GOA is a high burden disease. This disease burden can impact not only on quality of life but also the tolerance of treatment. A recent study in China demonstrated that the early integration of nutritional and psychological support alongside SACT provided a survival advantage in advanced GO cancer (14.8 vs. 11.9 months; HR, 0.68; P=0.021) (96). No difference in frequency of adverse events was observed. Where available, early supportive care should therefore be offered to patients.

**5. Future direction**

For all patients, both cancer and the systemic treatments offered by oncologists are significant stressors that have the potential to challenge physiological reserve. For those patients with advanced disease, the delivery of treatment can be challenging, and the impact of treatment can be unpredictable and significant.

There is a recognised mismatch between the age of patients with advanced GOA encountered in clinical practice (median age, 74 years) and trial populations (REAL2 trial; median age, 63 years) (13). There is similar but less measurable mismatch in other measures such as frailty, performance status and co-morbidity. This issue is not unique to upper gastrointestinal cancer. The ageing population in the Western world can be expected to lead to a marked increase in the number of older patients seeking systemic anticancer therapy over the coming decades (97).

A lack of evidence in older-aged frail patients across tumour groups impacts negatively upon treatment delivery and effectiveness, as well as health-related quality of Life.
(HRQoL). These factors lead to uncertainty in selecting optimal regimens to achieve the best balance of cancer control, toxicity, patient acceptability and quality of life in older and frailer patients.

With the emerging role of immune checkpoint inhibitors and other targeted therapies in advanced GOA, it is important to include patients who represent our real-world patients in terms of age and frailty in prospective trials.

To address this issue, the inclusion of frailer patients in clinical trials, who more resemble those encountered in practice, as well as the incorporation of appropriate endpoints has been highlighted as a priority for the American Society of Clinical Oncology (ASCO), the International Society of Geriatric Oncology (SIGO) and the European Organization for Research and Treatment of Cancer (EORTC). They have produced reports on the topic (73,98-100) and have suggested removing the upper age limit of trials and the design of specific trials for older patients where standard therapy is not feasible with integrated appropriate measures of outcome.

Consideration should be given to identifying relevant clinical and translational questions and designing trials appropriately to address them. With an older, frailer population, these questions may involve issues relating to dose de-escalation to achieve a balance of efficacy and toxicity or validating novel endpoints. In the complex world of geriatric oncology where there is huge variation in patient fitness and circumstances, communication with patients and families is essential. The GO2 trial is an exemplar of this approach. The data from the GO2 trial offers the opportunity to develop a decision aid based on objective assessments of frailty and both clinical and patient reported outcomes.

In the absence of evidence from clinical trials, the role of real-world data should not be ignored. These data can provide insight into outcomes post-drug approval in patient groups not adequately represented in clinical trials. This can aid clinical decision making but also accelerate progress in developing appropriate future studies.

6. Conclusion

The real-world patient cohort of patients with advanced GOA differs from traditional trial populations. Palliative chemotherapy is effective in older and frail patients, but it is vital to monitor patients closely for toxicity. The proper selection of patients is paramount, and this highlights the importance of integration of frailty screening and geriatric assessment, multi-disciplinary team (MDT) input and toxicity prediction tools into decision making. In the future, there should be a move to make clinical trials more applicable to real-world populations.

Acknowledgements

Not applicable.

Funding

MAB is a clinical academic fellow funded by the Chief Scientist Office in Scotland.

Availability of data and materials

Not applicable.

Authors’ contributions

MAB and SOH developed the concept for the study. MAB, SOH and RDP drafted the manuscript. RDP, PSH and DS reviewed and edited the manuscript. All authors read and approved the final draft. MAB and RDP confirm the authenticity of all the raw data.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

MAB received funding from Servier and BMS to attend meetings. RDP has undertaken speaking, consulting and advisory roles for Eli Lilly, BMS, Pfizer, Sanofi and Servier, and received research funding (not related to the work in this manuscript) from Astra Zeneca, Roche, MSD, Merck serrano, Eli Lilly, Five Prime Therapeutics, Clovis, Boston Biomedical, and Janssen. PSH, DS and SOH have no competing interests to declare.

References

1. Edgren G, Adami HO, Weiderpass E and Nyrén O: A global assessment of the oesophageal adenocarcinoma epidemic. Gut 62: 1406-1414, 2013.
2. UK CR: Oesophageal Cancer, 2020.
3. Shitara K, Muro K, Matsuo K, Ura T, Takahari D, Yokota T, Sawaki A, Kawai H, Ito S, Munakata M and Sakata Y: Chemotherapy for patients with advanced gastric cancer with performance status 2. Gastrointest Cancer Res 3: 220-224, 2009.
4. Offman J, Pesola F and Sasiemi P: Trends and projections in adenocarcinoma and squamous cell carcinoma of the oesophagus in England from 1971 to 2037. Br J Cancer 118: 1391-1398, 2018.
5. Merchant SJ, Brogly SB, Booth CM, Goldie C, Nanoji S, Patel SV, Lajkosz K and Baxter NN: Palliative care and symptom burden in the last year of life: A population-based study of patients with gastrointestinal cancer. Ann Surg Oncol 26: 2336-2345, 2019.
6. Handforth C, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ and Young J: The prevalence and outcomes of frailty in older cancer patients: A systematic review. Ann Oncol 26: 1091-1101, 2015.
7. Besharat S, Jabbari A, Semnani S, Keshkhar A and Marjani J: Inoperable esophageal cancer and outcome of palliative care. World J Gastroenterol 14: 3725-3728, 2008.
8. Fontana E and Smyth EC: Novel targets in the treatment of advanced gastric cancer: A perspective review. Ther Adv Med Oncol 8: 113-125, 2016.
9. Murad AM, Santiago FF, Petruccelli A, Rocha PR, Rodrigues MA and Rausch M: Modified therapy with 5-fluourouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72: 37-41, 1993.
10. Partnership HQI: National Oesophago-Gastric Cancer Audit-An audit of the care received by people with oesophago-gastric cancer and oesophageal high grade dysplasia in England and Wales, 2019.
11. Swinson D, Hingorani M, Stokes Z, Dent J, Gupta K, Chatterjee A, Kampiosioras K, Grumett SA, Khan M, Marshall H, et al: Best supportive care (BSC) with or without low-dose chemotherapy (chemo) in frail elderly patients with advanced gastroesophageal cancer (aGOAC): The uncertain optimism of the GO2 phase III trial. J Clin Oncol 37: 4051-4051, 2019.
12. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Yamauchi Y, Satoh T, et al; Trastuzumab in combination with chemotherapy versus chemotherapy alone as first-line treatment for HER2-positive advanced gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
13. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J and Norman AR: Upper Gastrointestinal Clinical Studies Group of the National Cancer Research: Caphetaxine and oxaliplatine for advanced esogastric cancer. N Engl J Med 358: 36-46, 2008.
14. Shiata K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudala I, Garrido M, Chung HC, Lee J, et al: Efficacy and safety of pembrolizumab or pembroliuzum plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: The KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol 6: 1571-1580, 2020.
15. Moheler M, Shiata R, Garrido M, Salmon P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu Y, et al; LB1441: Pembrolizumab (nivo) plus chemotherapy (versus chemo as first-line) (IL) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJ/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study. Ann Oncol 31 (Suppl 4): S1191, 2020.
16. Hall JS, Wands J, Klotz L, Kanzler R, Holm C, Jones M, Lowe C, Howard H, Swinson D, Velikova G, Anthony A, et al: A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastro-esophageal cancer (321GO). Br J Cancer 116: 472-472, 2017.
17. Swaminathan D and Cunningham V: Geriatric oncology: Problems with under-treatment within this population. Cancer Biol Med 12: 275-283, 2015.
18. Trumper M, Ross P, Cunningham D, Norman AR, Hawkins R, Seymour M, Harper P, Iveson T, Nicolson M and Hickish T: Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. Eur J Cancer 42: 827-834, 2006.
19. Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, Falandry C, Artz A, Brain E, Colloca G, et al: International society of geriatric oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 32: 2595-2603, 2014.
20. Wagner AD, Syn NL, Moheler M, Grothe W, Yong WP, Tai BC, Ho J and Unverzagt S: Problems with under-treatment within this population. Cancer Biol Med 12: 275-283, 2015.
21. Trumper M, Ross P, Cunningham D, Norman AR, Hawkins R, Seymour M, Harper P, Iveson T, Nicolson M and Hickish T: Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. Eur J Cancer 42: 827-834, 2006.
22. Arends J: Struggling with nutrition in patients with advanced cancer: Nutrition and nourishment-focusing on metabolism and supportive care. Annals of Oncology (Suppl 2): ii27-ii34, 2018.
23. Amarya S, Singh K and Sabharwall M: Changes during aging and their association with malnutrition. J Clin Gerontol Geriatr 6: 78-80, 2020.
24. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S and Gutchrie B: Epidemiology of multimorbidity and implications for health care, research, and medical education: A cross-sectional study. Lancet 380: 75–82, 2012.
25. Cincinnati MD, Velutini C, Bonardi C, Quarleri L, Cappello S, Garvani A, Rondanelli M and Caccialanza R: Nutrition support and anti-cancer treatment. Ann Oncol 19: v52–v55, 2008.
26. Bellon A, Li Lazzaro L and Koverech A: Nutritional support and clinical outcome in advanced cancer patients. Proc Nutr Soc 77: 388-393, 2018.
27. Eyigor S and Akdeniz S: Is exercise ignored in palliative cancer patients? World J Clin Oncol 5: 554-559, 2014.
28. Wadsley J, Di Lorenzo Z, Stoelzle D, van der Mark C, Carpenter CR, Avidan MS and Stark S: Systematic review of falls in older adults with cancer. J Geriatr Oncol 6: 70-83, 2015.
29. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Bhatia S, Katheria V, et al: Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J Clin Oncol 29: 3457-3465, 2011.
30. Wildes TM, Ruwe AP, Fournier C, Gao F, Carson KR, Piccirillo JF, Tan B and Colditz GA: Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer. J Geriatr Oncol 4: 227-234, 2013.
31. Drogan E and Moorthy K: Prehabilitation for esophagectomy. J Thorac Dis 11 (Suppl 5): S632-S638, 2019.
32. Faithfull S, Turner L, Poole K, Joy M, Manders R, Weprin J, Winters-Stone K and Saxton J: Prehabilitation for adults diagnosed with cancer: A systematic review of long-term physical function, nutrition and patient-reported outcomes. Eur J Cancer Care (Engl) 28: e13023, 2019.
33. Minnella EM, Awasthi R, Loiselle SE, Agnihotram RV, Ferri LE and Carli F: Effect of exercise and nutrition prehabilitation on functional capacity in esophagogastric cancer surgery: A randomized clinical trial. JAMA Surg 153: 1081-1089, 2018.
34. Hall CC, Cook J, Maddocks M, Skipworth RJE, Fallon M and Laird BJ: Combined exercise and nutritional rehabilitation in outpatients with incurable cancer: A systematic review. Support Care Cancer 27: 2371-2384, 2019.
35. Cancer Research UK: Improving Cancer Treatment and Care for an Ageing Population. Cancer Research UK, London, 2018. https://www.cancerresearchuk.org/sites/default/files/advancing_care_advancing_years_full_report.pdf. Accessed November 4, 2020.
36. Soto-Perez-de-Celis E, Li D, Sutcliffe CM, Kim K, Twardowski P, Fakih M, Chung VM, Cristea CM, Lim D, Yuan Y, et al: Patient-defined goals and preferences among older adults with cancer starting chemotherapy (CT). J Clin Oncol 36: 10009, 2018.
37. Cancer Research UK: Cancer mortality by age. https://www.cancerresearchuk.org/health-professional/cancer-statistics/mortality/age. Accessed November 4, 2020.
38. Popescu RA, Norman A, Ross PJ, Parikh B and Cunningham D: Adjutant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17: 2412-2418, 1999.
39. Al-Batran SE, Pauligk C, Homann NT, Hartmann JT, Moehler M, Probst S, Rethwisch V, Stoechmuller-Weiss J, Prasinakis N, Hollerbach S, et al: The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the arbeitsgemeinschaft innereis- tische onkologie (FLLOT65). Eur J Cancer 49: 835-842, 2013.
40. Morley JE, Vellas B, van Kan GA, Rockwood K, Song X, MacKnight C, Mitnitski A, K enclave PL, Pohflepp D, et al: Frailty consensus: A call to action. J Am Med Dir Assoc 14: 392-397, 2013.
41. Kelly CM and Shahrkani A: Moving beyond karnofsky and eCOG performance status assessments with New technologies. J Oncol 2016: 6186043, 2016.
42. Kirkuks L, Šaltytė Benth J, Rostoft S, Grønbech HG, Hjemstad MJ, Selbaek G, Wyrwicz L, Skoczylas T, Campos Bragagnoli A, Liu Y, et al; Trastuzumab in combination with chemotherapy versus chemotherapy alone as first-line treatment for HER2-positive advanced gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
43. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I and Mitnitski A: A global clinical measure of fitness and frailty in elderly people. CMAJ 173: 489-495, 2005.
44. Soubeyran P, Bellera CA, Gregoire F, Blanc J, Ceccaldi J, Mortier CS, Boffa MD, Foncek M and Rainfray M: Validation of a screening test for elderly patients in oncology. J Clin Oncol 26: 20568-20568, 2008.
86. Dutton SJ, Ferry DR, Blazey JM, Abbas H, Dahle-Smith A, Mansoor W, Thompson J, Harrison M, Chatterjee A, Falk S, et al: Gefitinib for oesophageal cancer progressing after chemotherapy (COG): A phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol 15: 894-904, 2014.

87. Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G and Reichardt P: Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47: 2306-2314, 2011.

88. Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyle D, Madhusudan S, Middleton GW, et al: Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): An open-label, phase 3 randomised controlled trial. Lancet Oncol 15: 78-86, 2014.

89. Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, et al: Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 19: 1437-1448, 2018.

90. Parikh JD, Hollingsworth KG, Wallace D, Blamire AM and MacGowan GA: Normal age-related changes in left ventricular function: Role of afterload and subendocardial dysfunction. Int J Cardiol 223: 306-312, 2016.

91. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, et al: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma ( REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383: 306-319, 2014.

92. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol 15: 1224-1235, 2014.

93. Elias R, Morales J, Rehman Y and Khurshid H: Immune checkpoint inhibitors in older adults. Curr Oncol Rep 18: 47, 2016.

94. Shitara K, Özgüröglu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglieve C, Chung HC, et al: Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial. Lancet 392: 123-133, 2018.

95. Adamson D, Byrne A, Porter C, Blazey J, Griffiths G, Nelson A, Sewell B, Jones M, Svobodova M, Fitzsimmons D, et al: Palliative radiotherapy after oesophageal cancer stenting (ROCS): A multicentre, open-label, phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol: Feb 18, 2021 (Epub ahead of print).

96. Lu Z, Fang Y, Liu C, Zhang X, Xin X, He Y, Cao Y, Jiao X, Sun T, Pang Y, et al: Early interdisciplinary supportive care in patients with previously untreated metastatic esophagogastric cancer: A Phase III randomized controlled trial. J Clin Oncol 39: 748-756, 2021.

97. Lord SR, Hall PS and Seymour MT: Are we representing the true population in oncology trials? Ann Oncol 20: 2022, 2009.

98. Hempenius L, Slaets JP, Boelens MA, van Asselt DZ, de Bock GH, Wiggers T and van Leeuwen BL: Inclusion of frail elderly patients in clinical trials: Solutions to the problems. J Geriatr Oncol 4: 26-31, 2013.

99. Whelehan S, Lynch O, Treacy N, Gleeson C, Oates A and O’Donovan A: Optimising clinical trial design in older cancer patients. Geriatrics (Basel) 3: 34, 2018.

100. Hurria A, Levit LA, Dale W, Mobile SG, Muss HB, Fehrenbacher L, Magnuson A, Lichtman SM, Bruinooge SS, Soto-Perez-de-Celis E, et al: Improving the evidence base for treating older adults with cancer: American society of clinical oncology statement. J Clin Oncol 33: 3826-3833, 2015.

101. Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaia H, Tokunaga S, Morishita E, et al: Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31: 4438-4444, 2013.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.